Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter ...

Bausch + Lomb BLCO recently announced the U.S. launch of the EyeGility Inserter, a preloaded intraocular lens (IOL) delivery ...

Bausch + Lomb has abandoned its next great hope in glaucoma after the eye drops flunked a phase 2 study. The eye health company had been evaluating the alpha-2B agonist, dubbed BL1107, in a mid-stage ...

This summer, Bausch + Lomb unveiled plans to acquire a dry eye disease treatment from Novartis for up to $2.5 billion. Now, the eye health company has closed the deal. The purchase of XIIDRA, a 5% a ...

Bausch + Lomb announced topline results from its phase 2 study of BL1107 in patients with glaucoma. According to the company, ...

Bausch + Lomb will stop developing a topical eye drop for glaucoma after the drug failed to meet its primary endpoint in a phase 2 study. The company on Thursday said the drug, BL1107, didn't ...

Bausch + Lomb said on Thursday its glaucoma eye drop had missed ​the main goal in a mid-stage ‌trial of replicating visual function improvements observed in a smaller study.

CEO Brenton L. Saunders reported "our constant currency revenue growth speaks to the breadth and depth of our portfolio and is driven by a mix of hero products and a steady stream of new introductions ...

Orphia, a voice-based AI agent that can call patients to discuss their upcoming cataract surgery and lens options, will soon ...

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It ...

About Bausch Health Cos. Inc. Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and ...